1. Foerster J, Bachman M (2015) Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments. Nanomedicine (Lond) 10: 1361-1369.
  2. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, et al. (2006) Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 36: 2857-2867.
  3. Jennings GT, Bachmann MF (2009) Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49: 303-3264.
  4. Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, et al. (2016) Development of an Interleukin-1beta Vaccine in Patients with Type 2 Diabetes. Mol Ther 24: 1003-1012.
  5. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, et al. (2006) Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 36: 2849-2856.;jsessionid=F2CF3FA42DF7BCF4691C7D591AA315B5.f02t02
  6. West J, Ogston S, Berg J, Palmer C, Fleming C, et al. (2017) HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol.
  7. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy
    Andris Zeltins, Jonathan West, Franziska Zabel, Aadil El Turabi, Ina Balke, Stefanie Haas, Melanie Maudrich, Federico Storni, Paul Engeroff, Gary T. Jennings, Abhay Kotecha, David I Stuart, John Foerster & Martin F. Bachmann